A novel analgesic for osteoarthritis may offer better pain relief than current options but at the risk of more progressive disease and higher rates of total joint replacement. Tanezumab, a monoclonal antibody blocking nerve growth factor, improved pain and physical function when compared to placebo in a trial of patients with moderate to severe OA ...
Better OA analgesia may come at the price of more joint damage
By Michael Woodhead
3 Jul 2019